Maintenance indication applies after response or stable disease following initial chemotherapy plus trastuzumab, with or without pertuzumab, in HR-positive, HER2-positive advanced breast cancer.
HER2-Positive Breast Cancer: Symptoms, Causes, Complications and Prevention: By Shreoshree Chakrabarty HER2-positive breast cancer is a distinct and aggressive subtype of breast cancer marked by the ...
Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results